Ionian Technologies Enters Into Manufacturing Agreement With Roche

Ionian Technologies and Roche Diagnostics have entered into a molecular diagnostic manufacturing agreement based on Ionian’s rapid isothermal nucleic acid amplification technology. Under this collaboration, Roche is expected to identify new applications and customers for the technology and will bring these opportunities to Ionian.

Roche is also expected to have exclusive manufacturing rights for these specific opportunities upon commercialisation.

Ionian’s isothermal amplification technology, the NEAR Assay provides for detection of both DNA and RNA from bacterial or viral pathogens in less than 10 minutes. Furthermore, the technology is amenable to raw or unpurified samples, obviating the need for complex sample processing and purification steps. Based on these key attributes, Ionian’s technology is ideally suited for point-of-care and point-of-use settings.

Andrew Miller, CEO of Ionian Technologies, said: “We are excited by this collaboration as it allows Ionian to continue to focus on its core strengths, including technology and assay development, while leveraging the business development, sales, and manufacturing expertise of Roche.”